+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Supportive Care Drugs Market Research Report by Therapeutic Class (Non-Steroidal Anti-Inflammatory Drugs, Antiemetics, and Bisphosphonates), Application, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 238 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5715521
UP TO OFF until Mar 31st 2023
The Global Cancer Supportive Care Drugs Market size was estimated at USD 19.83 billion in 2022, USD 20.62 billion in 2023, and is projected to grow at a CAGR of 4.43% to reach USD 28.06 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Cancer Supportive Care Drugs Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Cancer Supportive Care Drugs Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Cancer Supportive Care Drugs Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Cancer Supportive Care Drugs Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Cancer Supportive Care Drugs Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Therapeutic Class, the market is studied across Non-Steroidal Anti-Inflammatory Drugs, Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents, Granulocyte-Colony Stimulating Factors, and Opioids.
  • Based on Application, the market is studied across Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Cancer Supportive Care Drugs Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Cancer Supportive Care Drugs Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Cancer Supportive Care Drugs Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Cancer Supportive Care Drugs Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Supportive Care Drugs Market, including Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Supportive Care Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Supportive Care Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Supportive Care Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Supportive Care Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Supportive Care Drugs Market?
6. What is the market share of the leading vendors in the Global Cancer Supportive Care Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Supportive Care Drugs Market?
Frequently Asked Questions about the Global Cancer Supportive Care Drugs Market

What is the estimated value of the Global Cancer Supportive Care Drugs Market?

The Global Cancer Supportive Care Drugs Market was estimated to be valued at $19.83 Billion in 2022.

What is the growth rate of the Global Cancer Supportive Care Drugs Market?

The growth rate of the Global Cancer Supportive Care Drugs Market is 4.4%, with an estimated value of $28.06 Billion by 2030.

What is the forecasted size of the Global Cancer Supportive Care Drugs Market?

The Global Cancer Supportive Care Drugs Market is estimated to be worth $28.06 Billion by 2030.

Who are the key companies in the Global Cancer Supportive Care Drugs Market?

Key companies in the Global Cancer Supportive Care Drugs Market include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA and Ipsen Pharma.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
5.1.1.2. Increasing approval and launch of new products
5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
5.1.2. Restraints
5.1.2.1. High cost of cancer supportive care drugs
5.1.3. Opportunities
5.1.3.1. Development of novel targeted therapies for the treatment of cancer
5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
5.1.4. Challenges
5.1.4.1. Side effects associated with consumption of drugs
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cancer Supportive Care Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Non-Steroidal Anti-Inflammatory Drugs
6.3. Antiemetics
6.4. Bisphosphonates
6.5. Erythropoiesis Stimulating Agents
6.6. Granulocyte-Colony Stimulating Factors
6.7. Opioids

7. Cancer Supportive Care Drugs Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Liver Cancer
7.5. Lung Cancer
7.6. Prostate Cancer
7.7. Stomach Cancer

8. Americas Cancer Supportive Care Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Cancer Supportive Care Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Acacia Pharma Group PLC
12.2. Amgen Inc.
12.3. Aphios Corporation
12.4. AstraZeneca PLC
12.5. Bayer AG
12.6. Celldex Therapeutics
12.7. GSK PLC
12.8. Helsinn Healthcare SA
12.9. Heron Pharma
12.10. Ipsen Pharma
12.11. Johnson & Johnson
12.12. Merck & Co.
12.13. Novartis International AG
12.14. Sanofi SA
12.15. Sun Pharmaceutical Industries Ltd.
12.16. Teva Pharmaceutical Industries Ltd.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing


List of Figures
FIGURE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY THERAPEUTIC CLASS, 2030
FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
FIGURE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
FIGURE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
FIGURE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
FIGURE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, 2018-2030 (USD MILLION)
FIGURE 30. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 32. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 33. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 34. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 40. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 41. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 42. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 44. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 45. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 46. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 62. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 55. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 56. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 72. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 100. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 137. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 143. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 160. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 161. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 163. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 172. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 173. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 174. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 175. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 176. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET MERGER & ACQUISITION
TABLE 178. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 179. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 180. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET INVESTMENT & FUNDING
TABLE 181. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 182. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • Acacia Pharma Group PLC
  • Amgen Inc.
  • Aphios Corporation
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • GSK PLC
  • Helsinn Healthcare SA
  • Heron Pharma
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...